Эффективность Цельноклеточных вакцин от коклюша против ацеллюлярных

[Olegan1980]

Информацию о вышеприведенном исследовании нашел у врача-инфекциониста Евгения Александровича Щербины на его страничке Вконтакте ,собственно он же и рекомендует в комментариях сделать хотя бы одну цельноклеточную АКДС.
Позволю процитировать его: - АКДС как раз предотвращает заражение. Но ацелюллярные вакцины оказались слабыми в этом плане, поэтому даже за рубежом уже рекомендую делать хотя бы одну цельноклеточную...

[Evgeniy_Sherbyn]

Да, есть такое дело.

IMPORTANCE:
Current acellular pertussis vaccines may not protect against transmission of Bordetella pertussis.
OBJECTIVE:
To assess whether a priming dose of whole-cell pertussis (wP) vaccine is cost-effective at reducing pertussis infection in infants.
DESIGN, SETTING, AND PARTICIPANTS:
Mathematical model of pertussis transmission fit to US incidence data in a simulation of the US population. In this simulation study conducted from June 2014 to May 2015, the population was divided into 9 age groups corresponding to the current pertussis vaccination schedule and fit to 2012 pertussis incidence.
INTERVENTIONS:
Inclusion of a priming dose of wP vaccine into the current acellular pertussis vaccination schedule.
MAIN OUTCOMES AND MEASURES:
Reductions in symptomatic pertussis incidence by age group, increases in wP vaccine-related adverse effects, and quality-adjusted life-years owing to changing vaccine schedule.
RESULTS:
Switching to a wP-priming vaccination strategy could reduce whooping cough incidence by up to 95% (95% CI, 91-98), including 96% (95% CI, 92-98) fewer infections in neonates. Although there may be an increase in the number of vaccine adverse effects, we nonetheless estimate a 95% reduction in quality-adjusted life-years lost with a switch to the combined strategy and a cost reduction of 94% (95% CI, 91-97), saving more than $142 million annually.
CONCLUSIONS AND RELEVANCE:
Our results suggest that an alternative vaccination schedule including 1 dose of wP vaccine may be highly cost-effective and ethically preferred until next-generation pertussis vaccines become available.

[Ссылки доступны только зарегистрированным пользователям ]